Federico Innocenti Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics Associate Director, Center for Pharmacogenomics and Individualized Therapy. Post-graduate School of Oncology, magna cum laude, University of Pisa, Pisa, Italy (eligible to practice as an oncologist in Europe) (2002 – 2006) Ph.D. in Pharmacology, Toxicology, and Chemotherapy [dissertation title: Pharmacogenomic studies on UDP-glucuronosyltransferases (UGTs) in cancer chemotherapy]. University of Pisa, Pisa, Italy (1999 – 2002) Post-graduate School of Clinical Pharmacology, magna cum laude, University of Pisa, Pisa, Italy. Equivalent to USA board-certified Clinical Pharmacologist (1994 – 1998) M.D., magna cum laude, School of Medicine, University of Pisa, Pisa, Italy (dissertation title: Experimental pharmacokinetics and cytotoxicity of paclitaxel) (1986 – 1993) Associate Professor with Permanent Tenure, University of North Carolina at Chapel Hill, School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC (December 2014 – present) Associate Director, Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC (2013 – present) Current funding: Alliance for Clinical Trials in Oncology Foundation – Translation of genomic data into biomarkers in patients enrolled in CALGB/SWOG C80405 Study. Innocenti F (PI) (6/10/15 – 6/9/17) $623,875 Alliance for Clinical Trials in Oncology Foundation – Analysis of biospecimens from the CALGB/SWOG C80405 Study. Innocenti F (PI) (2/17/15 – 2/16/17) $254,095 NIH/NCI/UM1 CA186704-02. Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN). Dees C, Hurwitz H (Co-PIs). Innocenti F (Co-I) (4/1/14 – 2/28/19) 1% salary recovery NIH/NCI/2P01 CA142538-06. Statistical methods for cancer clinical trials. Kosorok M (PI). Innocenti F (Co-I) (4/1/15 – 3/31/20) 4.6% salary recovery NIH/2R01 GM047845-25. Semiparametric Analysis of Censored Data in Current Medical Studies. Lin D (PI). Innocenti F (Co-I) 5% salary recovery    
Relevant peer-reviewed publications
  1. Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, Innocenti F. Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients. Clin Cancer Res. 2016 Aug 9. PubMed PMID: 27507617.
  2. Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology.. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med. 2016 Sep;5(9):2249-60. PubMed PMID: 27465221.
  3. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 Aug 1;34(22):2602-9. PubMed PMID: 27138575; PubMed Central PMCID: PMC5012690.
  4. Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):1067-75. PubMed PMID: 26134224; PubMed Central PMCID: PMC4494119.
  5. Paré-Brunet L, Glubb D, Evans P, Berenguer-Llergo A, Etheridge AS, Skol AD, Di Rienzo A, Duan S, Gamazon ER, Innocenti F. Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat. 2014 Feb;35(2):227-35. PubMed PMID: 24186849; PubMed Central PMCID: PMC3935516.
  6. Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol. 2013 Sep;76(3):370-80. Review. PubMed PMID: 23701381; PubMed Central PMCID: PMC3769665.
  7. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15;18(2):577-84. PubMed PMID: 22142827; PubMed Central PMCID: PMC3412624.
  8. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15;17(16):5257-67. PubMed PMID: 21712447; PubMed Central PMCID: PMC3156871.
  9. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617-22. PubMed PMID: 20606091; PubMed Central PMCID: PMC2917317.
  10. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15;22(8):1382-8. PubMed PMID: 15007088.